




PCT/EP2003/012508



INVESTOR IN PEOPLE



EPO - DG 1
02.12.2003
(108)


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 13 November 2003

**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



00NOV02 E761879-1 001030
P01/7700 0.00-0226020.6

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference	JNR/NM/P33145		
2. Patent application number (The Patent Office will fill in his part)	07 NOV 2002	0226020.6	
3. Full name, address and postcode of the or of each applicant (<i>underline all surnames</i>) Patents ADP number (<i>if you know it</i>) If the applicant is a corporate body, give the country/state of its incorporation	Glaxo Group Limited Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, Great Britain United Kingdom 473587003		
4. Title of the invention	A Holder		
5. Name of your agent (<i>if you have one</i>) "Address for service" in the United Kingdom to which all correspondence should be sent (<i>including the postcode</i>) Patents ADP number (<i>if you know it</i>)	Corporate Intellectual Property GlaxoSmithKline Corporate Intellectual Property (CN9 25.1) 980 Great West Road BRENTFORD Middlesex TW8 9GS 7960982003		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (<i>if you know it</i>) the or each application number	Country	Priority application number (<i>if you know it</i>)	Date of filing (<i>day / month / year</i>)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (<i>day / month / year</i>)	
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (<i>Answer yes if:</i> a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is named as an applicant, or c) any named applicant is a corporate body See note (d)			

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form	0
Description	19
Claim(s)	5 <i>DM</i>
Abstract	1
Drawings	15 <i>only</i>

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. We request the grant of a patent on the basis of this application
Signature *J N Rice* Date 7-Nov-02

12. Name and daytime telephone number of person to contact in the United Kingdom
J N Rice 01279 644508

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- For details of the fee and ways to pay please contact the Patent Office.*

A Holder

5 Field of the Invention

The present invention relates to a holder for holding a dispensing container system which is adapted to dispense a quantity of a fluid contained therein on movement thereof relative to the holder, and is particularly, but not
10 exclusively, concerned with a holder for holding an aerosol canister.

Background of the Invention

A holder for an aerosol canister which acts as an actuator for the canister
15 on relative movement therebetween is known in the field of inhalation devices, for instance the nasal inhaler marketed under the trade name Beconase® (GlaxoSmithKline) in which the aerosol canister contains a drug (beclomethasone dipropionate) formulated in a pressurised fluid propellant.

20 In the Beconase® device the aerosol canister has a canister body holding the drug formulation which is capped with a valve assembly comprising a valve stem through which the drug formulation is selectively discharged from the canister body. The valve stem is biased to an extended (closed) position relative to the canister body by a spring or the like in the valve assembly. In the extended
25 position the valve stem places the drug formulation in fluid communication with a metering chamber in the valve assembly. This is the metering state and the metering chamber is sealed from the external environment in this state. The valve stem is movable against the biasing force to a retracted (open) position relative to the canister body. In the retracted position the valve stem places the
30 metering chamber in fluid communication with the external environment whereby the metered quantity of the drug formulation in the metering chamber is exhausted from the canister for administration to the patient. This is the discharge state and in this state the metering chamber is sealed from the interior of the canister body.

The holder has a hollow tube-like container part with a cavity which receives the canister therein. As known in the art, a base of the cavity presents a hollow stem block to receive the valve stem in stationary relation thereto. An outlet nozzle sized to be received in a patient's nostril extends outwardly from the outer surface of the container part. The stem block has an orifice which is oriented towards the nozzle.

In use, the patient depresses the canister into the cavity of the container part thereby resulting in the canister body moving relative to the valve stem to bring the valve stem to its retracted position. This causes a metered amount of the drug formulation to be discharged from the valve stem and directed out of the nozzle by the stem block to be delivered to the patient's nostril.

In addition to the container part, the holder has a closure part which is hinged to the mouth area of the cavity of the container part so as to be hingeable from a closed position, in which the closure part co-operates with the container part to enclose the canister and the nozzle, to an open position in which the closure and container parts are arranged "back-to-back" to expose the canister and nozzle. In the closed position the holder acts as a protective casing for the inhalation device, while in the open position the patient can use the holder as an applicator for gripping the inhalation device when administering the drug.

A drawback of such an inhalation device is that there is no dose counter to count the number of doses of the drug delivered to the patient so that the number of doses left is known.

It would be useful to provide a holder of the type defined which is adapted to advance a dose counter on relative movement of the dispensing container system thereto.

Summary of the Invention

According to the present invention there is provided a holder for holding a dispensing container system which is adapted to dispense a quantity of a fluid contained therein on movement thereof relative to the holder and further includes a dispensing counter means for counting the number of quantities of the fluid dispensed, the holder having a moulded plastics body with inner and outer surfaces, the inner surface bounding a cavity adapted to receive the dispensing container system in movable relation thereto, the cavity having a moulded counter advance means which is adapted in use to engage the dispensing counter means on relative movement between the dispensing container system and the body to advance the dispensing counter means to indicate the dispensing of a quantity of the fluid, the body being formed with an outlet port in communication with the cavity such that the fluid dispensed from the dispensing container system is dischargeable therethrough, and an aperture extends through the body from the outer surface to the inner surface in alignment with the counter advance means.

The aperture is created in the moulding process by that part of the mould which forms the counter advance means. The aperture provides the means by which the mould part is extracted from the body after it has been moulded. This is particularly advantageous where the counter advance means is unable to be formed by a mould part extending through the outlet port, for example due to the size of the outlet port as in the case where the outlet port is in the form of a nozzle sized to be received in a nostril of a nose of a human patient, and/or where the counter advance means is non-aligned with the outlet port.

The counter advance means may be a rack-like means, for instance a rack-like member or post.

In an embodiment of the invention, such as hereinafter described, the cavity extends along an axis of the holder and the dispensing container system is axially, slidably movable in the cavity to dispense therefrom. The body may be adapted to receive the dispensing container system in the cavity only when it is arranged in a predetermined orientation about an axis thereof. The axis of the

dispensing container system preferably extends between a trailing end and a leading end of the dispensing container system. The counter means may be located at the leading end and the body adapted to prevent rotation of the counter means in the cavity from the predetermined orientation.

5

Preferably, the body is provided with an alignment feature for aligning the system in the predetermined orientation. As an example, the alignment feature may be a slot in the body along which the system is slidable, as in the embodiment hereinafter described. Moreover, the slot may be adapted to engage the counter means to prevent its rotation in the cavity.

10

In an embodiment of the invention, such as hereinafter described, the counter means has a display part for displaying indicia to indicate the count and the body has a window for registering with the display part. The window may form part of the alignment feature, e.g. the slot at least in part extends from the outer surface to the inner surface. Conveniently, it is the display part which is slidable in the slot and/or which the slot engages for anti-rotation of the counter means.

15

20

The holder may have a hollow stand structure with a passageway in fluid communication with the outlet port, an outlet member of the container system through which fluid is dispensed being receivable in the passageway so that the passageway is able to channel fluid dispensed from the outlet member to the outlet port. The passageway may have an entrance opening into which the outlet member is insertable, and an exit opening aligned with the outlet port. The exit opening may be spaced from the outlet port by a void area, as in the embodiment hereinafter described.

25

In an embodiment of the invention, such as hereinafter described, the counter advance means and/or stand structure is located on a base surface of the cavity. The counter advance means may be positioned to a side of the stand structure.

30

Preferably, the body is formed by injection moulding.

According to the invention there is further provided the holder of the invention and the dispensing container system or the counter means thereof.

5 The system may comprise a container and the counter means. The container and counter means may be secured, fixedly or releasably, to form a unitary structure, or independent parts. In the latter case, the counter means may be mounted in the cavity, e.g. permanently.

10 The container may have an outlet member and a container member which contains the fluid and is movable relative to the outlet member to dispense the fluid from the outlet member. The container system may dispense when the container member is moved relative to the outlet member and the stand structure may be adapted to hold the outlet member stationary relative to the body so that
15 the container member is movable in the body relative to the outlet member.

Ideally, the outlet member is at the leading end of the container system.

As in the embodiment hereinafter described, the container may be an
20 aerosol container, in which case the outlet member may form a part of a valve mechanism secured to the container member which is selectively openable by movement of the container member in the body relative to the outlet member.

Preferably, the container system has a metering mechanism for
25 dispensing metered doses of the fluid and the dispensing counter means is adapted to count the number of doses dispensed. To this end, the valve mechanism may be a metering valve.

The fluid in the dispensing container system may be a drug or
30 pharmaceutical composition, e.g. a suspension or solution of a drug in a liquified gas propellant, such as HFA 134a or HFA 122. The drug may be for the treatment or prophylaxis of a respiratory disease or disorder, for instance rhinitis.

A non-limiting exemplary embodiment of the invention will now be described with reference to the accompanying FIGURES of drawings.

Brief Description of the Drawings of the Exemplary Embodiments

5

FIGURE 1 is a schematic view of a patient using an intranasal device having an inner actuating part in accordance with the invention.

10

FIGURE 2 is a side view of the intranasal device showing an outer casing part thereof comprising cover and container members and a hinge therebetween, the outer casing part in a closed state to protect inner parts of the device.

15

FIGURE 3 is a side view of the intranasal device with the outer casing part hinged to an open state to allow access to the inner parts.

FIGURE 4A is a side view of the intranasal device in its open state with the cover member pivoted behind the container member

20

FIGURE 4B corresponds to FIGURE 4A, but with the container and cover members nested.

FIGURE 5 is a rear view of the device with the outer casing part in its closed state.

25

FIGURE 6 is an exploded perspective view of the intranasal device with the outer casing part in its nested state.

30

FIGURE 7 is a schematic, partial sectional side view of the inner actuating part of the intranasal device mounted in the outer casing part .

FIGURE 8 is a enlarged fragmentary view of an alternative hinge construction for the outer casing part.

FIGURE 9 is a cross-sectional side view of the alternative hinge construction along line IX-IX in FIGURE 8.

FIGURE 10A is a perspective view of a canister unit of the intranasal device comprising a canister and a dose counter head mounted on the canister.

FIGURE 10B is a plan view of the dose counter head.

FIGURE 10C is a side view of the dose counter head.

FIGURE 10D is a rear view of the dose counter head.

FIGURE 11 is schematic side view, partly in section, of the inner actuating part of the intranasal device.

FIGURE 12 is an opposite side view of the inner actuating part with the canister unit shown mounted therein in ghost.

FIGURE 13 is a plan view of the inner actuating part.

FIGURE 14 is a rear view of the inner actuating part with the canister unit mounted therein.

FIGURE 15A is a schematic side view, partly in cross section, of the canister unit mounted in the inner actuating part in an inoperative position.

FIGURE 15B corresponds to FIGURE 15A, but with the canister unit in an operative position relative to the inner actuating part.

Detailed Description of the Exemplary Embodiment

In the FIGURES of drawings there is shown a drug delivery device 1 in accordance with the present invention, the device 1 in this particular non-limiting

embodiment being an intranasal drug delivery device, as shown graphically in FIGURE 1.

As best shown in FIGURE 6, the intranasal drug delivery device 1 comprises as component parts the following:-

- an outer casing part 3;
- a one-piece inner actuating part 5 which is releasably securable in the outer casing part 3; and
- a canister unit 7 releasably securable in the inner actuating part 5.

Outer Casing Part

Referring to FIGURES 2 to 7, the outer casing part 3 of the intranasal device 1 is formed from two shell-like members, namely a container member 9 and a cover member 11, which are connected to one another through a hinge 13. The container and cover members 9, 11 each respectively present a cavity 17a; 17b having a mouth bound by a lip surface 2a; 2b (FIGURE 6).

Both the container member 9 and the cover member 11 are formed from a plastics material by injection moulding, although other types of moulding processes can, of course, be used. The container and cover members 9, 11 are preferably both formed from polypropylene with the container member 11 being opaque, but with the cover member 11 being transparent or semi-transparent. Other plastics material combinations are possible, although it is preferable for the cover member 11 to be transparent/semi-transparent for reasons which will become apparent hereinafter.

As shown in FIGURE 7, for example, the cover member 11 is integrally formed with the hinge 13, colloquially known as a "living hinge", and the hinge 13 includes a knob 15.

Turning to FIGURES 6 and 7, on an inner surface 19 of the cavity 17a of the shell-like container member 9 there is formed a pair of protrusions or ribs 21a, 21b to co-operate with complementary surfaces of the inner actuating part 5 to form a snap-fit connection between the outer casing part 3 and the inner actuating part 5, as will also be discussed in more detail hereinafter. A first one of the ribs 21a is disposed towards an upper end 23 of the container member 9, whereas the other rib 21b is disposed towards a lower end 25 of the container member 9.

Also formed on the inner surface 19 of the cavity 17a of the container member 9 are longitudinally extending ribs 27a, 27b. The longitudinal ribs 27a, 27b are disposed on opposing sides of the container member 9 and act as anti-rotational retainers on the inner actuating part 5 in the cavity 17a.

At the upper end 23 of the container member 9 there is formed a bevel 29 through which an aperture 31 extends from an outer surface 33 of the container member 9 to the inner surface 19 of the cavity 17a. From FIGURE 7 it will be seen that the aperture 31 is adapted to receive the knob 15 on the hinge 13. Although the diameter of the knob 15 is greater than the diameter of the aperture 31, the knob 15 is able to be pushed through the aperture 31 for capture therein due to the container and cover members 9, 11 being sufficiently resiliently deformable due to their shell-like nature and the materials used. Moreover, the knob 15 is able to be withdrawn from the aperture 31 upon application of a sufficient pulling force thereto for separation of the container and cover members 9, 11.

As shown in FIGURES 2 to 5, the mounting of the knob 15 of the hinge 13 in the aperture 31 of the container member 9 enables two degrees of movement of the cover member 11 on the container member 9 as follows:-

- (1) Hinging of the cover member 11 from a closed position shown in FIGURES 2 and 5, in which the respective lip surfaces 2a, 2b of the

cavities 17a, 17b of the container and cover members 9, 11 abut one another at an interface 2c to form an enclosed internal space 8 (see FIGURE 7), to an open position shown in FIGURE 3, in which the cavity 17a of the container member 9 is accessible. As will be understood from FIGURES 6 and 7, the lip surfaces 2a, 2b are each provided with detent elements 4, 6 which engage with one another in the closed position to provide a releasable snap-fit fastening of the container and cover members 9, 11 in the closed position.

- (2) Rotary or pivotable movement of the cover member 11 about the aperture 31 (pivot axis A-A) from a first angular position corresponding to the open position shown in FIGURE 3 to a second angular position shown in FIGURE 4A in which the cover member 11 is located behind the container member 9. The cover member 11 is not able to be pivoted about the pivot axis A-A from its closed position due to the interengagement of the lip surfaces 2a, 2b.

As shown in FIGURE 4B, when the cover member 11 is in the second angular position it is able to nest with the container member 9 by forward movement in the direction of arrow B. In other words, the concave cavity 17b of the shell-like cover member 11 is able to slidably receive the convex rear surface of the container member 9. In the nesting position, an interference fit is formed between the container and cover members 9, 11 to releasably fasten them in the nesting position.

When the container and cover members 9, 11 adopt the nesting configuration, an ergonomic unit is formed which is able to be easily, and comfortably, held by a hand 90 of a patient 92, as shown in FIGURE 1. In this mode, the outer casing part 3 is able to act as a holder or applicator of the drug delivery device 1.

As shown in FIGURE 5, for example, the outer surface 33 at the rear side of the container member 9 is provided with a window 35. As will be understood

from FIGURES 4A and 4B, the window 35 is covered by the cover member 11 when in its second angular position. If the cover member 11 is transparent or semi-transparent, the window 35 is then visible through the cover member 11 when in its second angular position.

5

If need be, an indexing or detent mechanism could be provided for indexing the cover member 11 in one or more predetermined angular positions about the pivot axis A-A, for instance the first and/or second angular positions and/or angular positions therebetween. The user would then have a tactile
10 feedback indicating that the cover member 11 is in the correct angular position, e.g. for nesting with the container member 9. One way of achieving the indexing mechanism would be a male-and-female arrangement in which male (or female) surface features are formed in the outer surface 33 of the container member 9 at the required angular dispositions about the pivot axis A-A and one or more
15 complementary female (or male) surface features are correspondingly arranged on the inner surface of the hinge 13 about the knob 15. When the male feature is located in the, or one of the, female features (or vice-versa), the cover member 11 is indexed in a predetermined angular position. To move the cover member 11 to a new angular position, rotation of the cover member 11 about the pivot
20 axis A-A causes disconnection of the first indexing connection until the male and female features re-engage at a new angular position of the cover member 11

By way of example, a "ball-and-socket" indexing mechanism is shown in FIGURES 8 and 9 in which a circular array of protrusions 80 is formed on the
25 inner surface of the hinge 13 co-axially with the knob 15, and a complementary circular array of sockets 82 is formed in the outer surface 33 of the bevel 29 on the container member 9 co-axially with the pivot axis A-A. When the protrusions 80 are located in the complementary sockets 82, the cover member 11 is indexed in one of a plurality of different predetermined angular positions it can adopt
30 about the pivot axis A-A, for instance the first angular position of FIGURES 2 and 3 or the second angular position of FIGURES 4A and 4B. The cover member 11 is then able to be indexed in a new predetermined angular position by pivoting it about the pivot axis A-A to disconnect and re-engage the protrusions 80 and

sockets 82, e.g. from the first angular position to the second angular position and vice-versa.

In an alternative embodiment, an indexing mechanism may be provided which indexes the cover member 11 in an end angular position between the first and second angular positions mentioned previously such that the cover member 11 does not cover the window 35 in the container member 9, thereby allowing the window 35 to be viewed by a user of the intranasal device 1.

10 Canister Unit

Turning attention now to FIGURES 10A to 10D, the canister unit 7 comprises an aerosol canister 10 of standard type which contains a drug formulated in a fluid propellant, e.g. a liquefied gas propellant such as a hydrofluoro alkane (HFA), for instance 1,1,1,2-tetrafluoroethane ($\text{CF}_3\text{CH}_2\text{F}$) (known as "HFA 134a") or 1,1,1,2,3,3,3-heptafluoro-n-propane ($\text{CF}_3\text{CHF}_2\text{CF}_3$) (known as "HFA 227") or a mixture thereof. The drug is typically for the treatment or prophylaxis of respiratory diseases or disorders, for example rhinitis. The drug may also be for the treatment or prophylaxis of other types of disease or disorder through systemic action of the drug. The canister unit 7 further comprises a dose counter head 12.

The canister 10 has a metal canister body 14 which, as known in the art, e.g. from metered dose inhalers (MDIs), has an open end which is capped by a valve assembly including a valve stem 16 which is mounted so it is movable relative to the canister body 14, between a retracted or open position relative to the canister body 14 in which the drug formulation is discharged from the canister 10 through the valve stem 16, and an extended or closed position relative to the canister body 14 in which the drug formulation is prevented from being discharged from the canister 10.

As known in the art, the valve assembly includes a biasing mechanism such as a spring (not shown) for biasing the valve stem 16 to the closed position.

The valve assembly may be such as to further include a metering mechanism which operates so that a metered dose of the drug formulation is discharged when the valve stem 16 is in its open position. Typically, the valve assembly will have a metering chamber of fixed volume which in the closed position of the valve stem 16 is sealed from the external environment but in fluid communication with the canister body 14 whereby the metering chamber is filled with the drug formulation, and which in the open position of the valve stem is sealed from the canister body 14 and its contents, but placed in fluid communication with the external environment so that the metered dose of the drug formulation in the chamber is discharged to the external environment through the valve stem 16.

The dose counter head 12 of the canister unit 7 has a hollow plastics body 18 of a plastics material which is fixedly secured to the canister 10 over the outlet end of the canister 10 having the valve assembly. The dose counter body 18 is fixed to the canister 10 to prevent it being taken off the canister 10, although it is free to rotate about a longitudinal axis D-D of the canister unit 7. The dose counter body 18 may be fixed to the canister 10 in the manner described and shown in WO01/28887 (Glaxo/Brand *et al*), the content of which is hereby incorporated herein by reference.

As best shown in FIGURE 10D, the dose counter body 18 is formed with a display window 20. The dose counter head 12 further includes a dose counting mechanism (not shown) in the body 18 which, when actuated, advances a counter 22 thereof located in the window 20. When the counter 22 is advanced it results in the dose count shown thereby in the window 20 either being incremented to indicate the number of doses dispensed or, more preferably, decremented to show the number of doses left in the canister 10. The dose counter mechanism can take one of the forms described and shown in WO98/56444 (Glaxo/Rand *et al*), the content of which is incorporated herein by reference.

An aperture 24 is provided in the outer surface of the dose counter body 18 to enable a driver to engage with the dose counting mechanism to advance

the counter 22 when a dose of the drug formulation is dispensed from the canister 10 by the inner actuating part 5, as will be described in more detail hereinafter.

5 As shown in FIGURES 10A and 10B, the dose counter body 18 comprises a skirt-like lower section 26 and a U-shaped upper section 28. The dose counter body 18 also has a central opening 13 to the U-shaped upper section 28 through which the valve stem 16 protrudes. It will further be seen from FIGURES 10C and 10D that the dose counter window 20 is formed in a protrusion 32 in the
10 outer peripheral surface of the U-shaped upper section 28.

Inner Actuating Part

 Attention is now turned to FIGURES 11 to 15B which show the inner
15 actuating part 5. The inner actuating part 5 is of a plastics material, preferably polypropylene, made by a moulding process, preferably by injection moulding.

 As will be seen, the inner actuating part 5 is of tubular construction having a main body 37 defining an axially-oriented cavity 38. The main body 37 has an
20 outer surface 39 having a rear section 40 of shape and size which is complementary to the shape and size of the inner surface 19 of the container member cavity 17a, thereby enabling the inner actuating part 5 to fit snugly in the container member cavity 17a, as shown in FIGURES 3 and 7, for example. More particularly, the rear section 40 of the main body outer surface 39 is provided with
25 a series of axially-spaced, circumferential ribs 41a-c which act as spacers to position the inner actuating part 5 along a vertical axis C-C in the container member 9, as shown in FIGURES 6 and 7. Moreover, as further shown in FIGURE 7, the uppermost circumferential rib 41a is adapted to be snap fit underneath the locking rib 21a on the inner surface 19 of the container member
30 9.

FIGURES 11 to 13 show that the circumferential ribs 41a-c are intersected by longitudinal slots 42, 44. The longitudinal slots 42, 44 are positioned and

●●

sized so as to co-operate with the longitudinal ribs 27a, 27b on the inner surface 19 of the container member 9 of the outer casing part 3 to prevent rotation of the inner actuating part 5 in the container member 9 of the outer casing part 3.

5 It will further be seen that the inner actuating part 5 has a foot structure 43 which, as shown in FIGURE 7, stands on a base surface 60 of the cavity 17a of the container member 9. The foot structure 43 includes a notch 45 on its forwardmost surface 47 which engages with the locking rib 21b at the lower end 25 of the cavity 17a of the container member 9. When the locking features 21a, 10 21b; 41a, 45 of the container member 9 and the inner actuating part 5 respectively engage with one another, the inner actuating part 5 is releasably fixed in place in the container member 9. Only when a sufficient separation force is applied is the inner actuating part 5 released from the container member 9.

15 The rear section 40 of the main body 37 of the inner actuating part 5 has a longitudinally extending guide slot 49. The guide slot 49 is sized to slidably receive the protrusion 32 on the dose counter body 18. The canister unit 7 can only be inserted into the inner actuating part 5 when the protrusion 32 is aligned with the guide slot 49 in the inner actuating part 5, as shown in FIGURE 6. Thus, 20 the guide slot 49 acts as a track along with the protrusion 32 slidably moves to insert the canister unit 7 into the inner actuating part 5 and retract it therefrom. The guide slot 49 also co-operates with the protrusion 32 to act as an anti-rotation feature which prevents rotation of the dose counter head 12 in the inner actuating part 5, as will be understood by reference to FIGURES 12 and 13.

25 As shown in FIGURE 13, the inner actuating part 5 also has longitudinal spacers 50 arranged circumferentially about the inner surface of the cavity 38 so that the canister unit 7 is generally co-axially mounted in the inner actuating part 5.

30 At the base of the cavity 38 of the inner actuating part 5 there is provided a hollow support 51 (so-called "stem block") having a sleeve 52 with a bore 53 sized to receive the valve stem 16 of the canister 10. It will be appreciated that

when the canister unit 7 is inserted axially into the cavity 38, the U-shaped upper section 28 of the dose counter head 12 encloses the support 51 on three sides thereof. The hollow support 51 includes a hollow extension 55 which extends outwardly at an acute angle α to the outer periphery of the sleeve 52. The extension 55 has a bore 57 which opens into the bore 53 of the sleeve 52.

The bore 57 of the extension 55 is co-axial with a longitudinal axis E-E of a nozzle 59 which extends forwardly and upwardly at an acute angle β to the outer peripheral surface of the body 37 of the inner actuating part 5. The acute angles α , β may be the same, or substantially the same. As shown in FIGURE 1, the nozzle 59 is shaped and sized to be received in a nostril 94 of a nose 96 of the patient 92.

FIGURE 15A shows the canister unit 7 mounted in the inner actuating part 5 with the valve stem 16 held in the bore 53 of the sleeve 52 of the hollow support 51. As will be understood by comparing FIGURES 15A and 15B, in operation the canister body 14 (and counter head 12) is depressed in the direction of arrow F relative to the inner actuating part 5 and the valve stem 16, the stem 16 being held stationary in the hollow support 51. This relative movement of the canister body 14 to the valve stem 16 causes a dose of the drug formulation to be discharged through the valve stem 16 into the bore 53 of the sleeve 52. The drug formulation is then channeled by the extension 55 into the nozzle 59 for delivery to the patient's nostril 94. The biasing mechanism in the valve assembly causes the canister body 14 to re-adopt the inoperative position shown in FIGURE 15A on release of the depressing force F ready for the next actuation cycle.

It can therefore be seen from the above that the inner actuating part 5 contains all of the actuating elements for causing actuation of the canister 10 so that the drug formulation is discharged therefrom into the patient 92. In other words, the inner actuating part 5 is adapted to actuate the canister 10 when separate from the outer casing part 3.

Moreover, the base of the cavity 38 of the inner actuating part 5 is moulded with a rack-like post 61 having a serrated outer profile 63 (teeth) which co-operates with the dose counter mechanism such that on depression of the canister body 14 in the inner actuating part 5 to its operative position shown in
5 FIGURE 15B, the rack-like post 61 drives a cog system in the dose counter mechanism (see WO98/56444 *supra*) so that the counter 22 in the display 20 is advanced to reflect that the canister 10 has been actuated to dispense a dose of the drug formulation.

10 It will be observed from FIGURES 11 to 13, for example, that the main body 37 of the inner actuating part 5 has an aperture 100 through a side thereof which is aligned with the rack-like post 61. The aperture 100 is left by that member of the inner actuating part mould assembly used to form the post 61. In this regard, it will be gathered from FIGURE 13 that the post 61 does not register
15 with the nozzle 59. That is to say, the post 61 is offset to the nozzle axis E-E such that it would not be possible to have the mould member for the post 61 extracted through the nozzle 59. This is because the nozzle diameter has to be small enough to be insertable into the patient's nostril 94 and the post 61 is positioned to one side of the hollow support 51 which is in registration with the
20 nozzle 59 for fluid communication therebetween.

As will be realised, the rack-like post 61 can be replaced by any other moulded dose counter mechanism driver structure as dictated by the form of the dose counter mechanism. Accordingly, the dose counter mechanism driver can
25 take the form of another type of mechanical element, for example. Again, reference may be had to WO98/56444 *supra*.

It can be seen from FIGURE 2 that once the canister unit 7 is assembled with the inner actuating part 5 and this assembly snap-fitted into the outer casing
30 part 3, the outer casing part 3 acts as a protective casing for the canister unit 7 when in its closed state as it prevents actuation of the canister unit 7 and shields the nozzle 59 of the inner actuating part 5.

Operation

To use the intranasal device 1, the patient 92 moves the cover member 11 of the outer casing part 3 from the closed position shown in FIGURE 2 to the open position shown in FIGURE 3. The cover member 11 is then pivoted to the second angular position shown in FIGURE 4A and then nested with the container member 9, as shown in FIGURE 4B. Then, as shown in FIGURE 1, the patient 92 grips the outer casing member 3 in one hand 90 and inserts the nozzle 59 into the nostril 94. The patient 92 then actuates the device 1 by depressing the canister body 14 into the inner actuating part 5 relative to the valve stem 16 with the index finger 98. This results in a metered dose of the drug formulation being delivered to the nostril.

Actuation of the device 1 can be confirmed by the patient 92 observing whether the dose counter 22 has been advanced (decremented/incremented). The patient 92 then closes the outer casing part 3 to protect the inner actuating part 5 and canister unit 7 until the next dose is required to be dispensed.

As will be seen from FIGURE 1, when the outer casing part 3 is in its open state it acts as a holder/applicator for the patient 92 in the sense that the patient 92 is able to grip the outer casing part 3 in one hand 90 and to depress the canister body 14 (and counter head 12) into the inner actuating part 5 with the index finger 98 to cause a dose of the drug formulation to be dispensed through the nozzle 59 and the counter 20 to be incremented/decremented.

One of the numerous advantages of the intranasal device 1 is the use of separable outer casing and inner actuating parts 3, 5. Recalling that the inner actuating part 5 contains all of the functional features for actuating the canister unit 7, both from a drug delivery and dose counting point of view, this is the only part which needs to be tested and submitted for regulatory approval. The outer casing part 3 does not affect the performance of the inner actuating part 5 in any way. This would be in contrast to the case where the outer and inner parts 3, 5

are integrally formed. In this instance, any change to the external shape and configuration after approval would necessitate a new application for approval since the alteration may have an adverse effect on the internal functional features, especially if the component is moulded from a plastics material.

5

So, the inner actuating part 5 is able to be designed first and then the decorative outer protective casing part 3 designed afterwards. In this way, the inner actuating part 5 can be tested and submitted for regulatory approval before the outer casing part 3 is finalised. This shortens the lead time for developing an approved drug delivery device. Moreover, the outer casing part 3 can be re-designed to maintain a contemporary appearance etc. without requiring a new round of regulatory tests.

It is to be understood that the exemplary embodiment of the present invention outlined above are for the purposes of illustration only, and that the invention can be modified, varied and take on other guises within the scope of the appended claims. Mindful of this, the use of reference numerals in the claims is not to be taken as having a limiting effect on the scope of the claims.

CLAIMS

1. A holder (5) for holding a dispensing container system (7) which is adapted to dispense a quantity of a fluid contained therein on movement thereof
5 relative to the holder and further includes a dispensing counter means (12) for counting the number of quantities of the fluid dispensed, the holder having a moulded plastics body (37) with inner and outer (39) surfaces, the inner surface bounding a cavity (38) adapted to receive the dispensing container system in movable relation thereto, the cavity having moulded counter advance means (61)
10 adapted in use to co-operate with the dispensing counter means on relative movement between the dispensing container system and the body to advance the dispensing counter means to indicate the dispensing of a quantity of the fluid, wherein the body is formed with an outlet port (59) in communication with the cavity such that the fluid dispensed from the dispensing container system is
15 dischargeable therethrough, and wherein an aperture (100) extends through the body from the outer surface to the inner surface in alignment with the counter advance means.
 2. The holder of claim 1 in which the counter advance means is a rack-like
20 means.
 3. The holder of claim 2 in which the rack-like means is a rack-like member or post.
 - 25 4. The holder of any one of the preceding claims in which the cavity extends along an axis of the holder and the dispensing container system is axially, slidably movable in the cavity to dispense therefrom.
 5. The holder of any one of the preceding claims in which the body is
30 adapted to receive the dispensing container system in the cavity only when it is arranged in a predetermined orientation about an axis (D-D) thereof.
-

6. The holder of claim 5 in which the axis of the dispensing container system extends between a trailing end and a leading end of the dispensing container system.
- 5 7. The holder of claim 6 wherein the counter means is located at the leading end and the body is adapted to prevent rotation of the counter means in the cavity from the predetermined orientation.
- 10 8. The holder of claim 5, 6 or 7 in which the body is provided with an alignment feature (49) for aligning the system in the predetermined orientation.
9. The holder of claim 8 in which the alignment feature is a slot (49) in the body along which the system is slidable.
- 15 10. The holder of claim 9 in which the slot is adapted to engage the counter means to prevent rotation thereof in the cavity.
- 20 11. The holder of any one of the preceding claims in which the counter means has a display part (20) for displaying indicia (22) to indicate the count and the body has a window (49) for registering with the display part.
12. The holder of claim 11 when appendant on any one of claims 8 to 11 wherein the window forms part of the alignment feature.
- 25 13. The holder of any one of the preceding claims in which the outlet port is in the form of a nozzle.
14. The holder of claim 13 in which the nozzle is sized to be received in a nostril (94) of a nose (96) of a human patient (92).
- 30 15. The holder of any one of the preceding claims wherein the counter advance means is non-aligned with the outlet port.

16. The holder of any one of the preceding claims further having a hollow stand structure (51) with a passageway (53) in fluid communication with the outlet port, an outlet member (16) of the container system through which fluid is dispensed being receivable in the passageway so that the passageway is able to
5 channel fluid dispensed from the outlet member to the outlet port.

17. The holder of claim 16 wherein the passageway has an entrance opening into which the outlet member is insertable, and an exit opening aligned with the outlet port.
10

18. The holder of claim 17 wherein the exit opening is spaced from the outlet port by a void area.

19. The holder of any one of the preceding claims wherein the counter advance means is located on a base surface of the cavity.
15

20. The holder of claim 19 when appendant on any one of claims 16 to 18 wherein the stand structure is on the base surface of the cavity.

20 21. The holder of claims 19 and 20 wherein the counter advance means is positioned to a side of the stand structure.

22. The holder of any one of the preceding claims wherein the body is formed by injection moulding.
25

23. The holder of any one of the preceding claims including the dispensing container system (7).

24. The holder of claim 23 in which the system comprises a container (10) to
30 which the dispensing counter means (12) is secured.

25. The holder of claim 23 or 24 wherein the container has an outlet member (16) and a container member (14) which contains the fluid and is movable relative to the outlet member to dispense the fluid from the outlet member.

26. The holder of claim 25 when appendant on claim 16 in which the container system dispenses when the container member is moved relative to the outlet member and the stand structure is adapted to hold the outlet member stationary relative to the body so that the container member is movable in the body relative to the outlet member.

27. The holder of claim 25 or 26 when further appendant on claim 6 in which the outlet member is at the leading end of the container system.

28. The holder of any one of claims 23 to 27 wherein the container is an aerosol container.

29. The holder of claim 28 when appended to claim 25 wherein the outlet member forms a part of a valve mechanism secured to the container member which is selectively openable by movement of the container member in the body relative to the outlet member.

30. The holder of any one of claims 23 to 29 wherein the container system has a metering mechanism for dispensing metered doses of the fluid and the dispensing counter means is adapted to count the number of doses dispensed.

31. The holder of claims 29 and 30 wherein the valve mechanism is a metering valve.

32. The holder of any one of claims 23 to 31 wherein the fluid is a drug composition.

33. The holder of any one of the preceding claims in which the body is moulded in a mould having a mould part which moulds the counter advance

means, the mould part being arranged in the mould so that it leaves the aperture in the body to enable its extraction from the body after the body has been moulded.

- 5 34. A holder substantially as hereinbefore described with reference to, and as illustrated by, the accompanying FIGURES of drawings.

ABSTRACT

A Holder

5 A holder (5) for holding a dispensing container system (7) which is adapted to dispense a quantity of a fluid contained therein on movement thereof relative to the holder and further includes a dispensing counter means (12) for counting the number of quantities of the fluid dispensed. The holder has a moulded plastics body (37) with inner and outer (39) surfaces. The inner surface bounds a cavity
10 adapted to receive the dispensing container system in movable relation thereto. The cavity has a moulded counter advance means (61) which is adapted in use to engage the dispensing counter means on relative movement between the dispensing container system and the body to advance the dispensing counter means to indicate the dispensing of a quantity of the fluid. The body is formed
15 with an outlet port (59) in communication with the cavity such that the fluid dispensed from the dispensing container system is dischargeable therethrough. Moreover, an aperture (100) extends through the body from the outer surface to the inner surface in alignment with the counter advance means.

20 (FIG. 12)

Fig. 1





Fig. 2



3/15

Fig. 3




Fig. 4A







Fig. 4B



6/15

Fig. 5





8/15

Fig. 7




Fig. 8





Fig. 9



10/15

Fig. 10A




Fig. 10B




Fig. 10C




Fig. 10D




Fig. 12





Fig. 11



13/15

Fig. 13




Fig. 14




Fig. 15A






Fig. 15B



PCT Application
PCT/EP2003/012508



INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/12508

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61M15/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98/56444 A (BONNEY STANLEY GEORGE; GODFREY JAMES WILLIAM (GB); RAND PAUL KENNE) 17 December 1998 (1998-12-17) page 8, line 4 -page 17, line 13; figure 7 ---	1-14, 16-32, 34,35
A	WO 96/26755 A (MARR CHRISTOPH THOMAS) 6 September 1996 (1996-09-06) page 3, line 28 -page 5, line 25; figures 1-3 ---	34,35
A	WO 02/00281 A (NORTON HEALTHCARE LTD; IVAX CORP (US)) 3 January 2002 (2002-01-03) page 10, line 5 -page 13, line 11 ---	1,4-6,8, 9,11-13, 15,22,34
E	EP 1 369 139 A (3M INNOVATIVE PROPERTIES CO) 10 December 2003 (2003-12-10) column 9, line 37 -column 23, line 3 ---	1-13, 15-32
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"A" document member of the same patent family

Date of the actual completion of the international search

26 April 2004

Date of mailing of the international search report

04/05/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kroeders, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/12508

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E,L	<p>WO 2004/001664 A (BONNEY STANLEY GEORGE; GODFREY JAMES WILLIAM (GB); RAND PAUL KENNE) 31 December 2003 (2003-12-31) page 18, line 10 -page 41, line 31 -----</p>	<p>1-14, 16-32</p>

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 03/12508

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 36
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 36

Claim 36 is drafted with reference to other parts of the description, contrary to Rule 6.2(a) PCT.

No International Search Report will be drawn up with regards to this claim (Articles 17(2)(a)(ii), 17(2)(b) PCT)

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/12508

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9856444	A	17-12-1998	AP 1126 A	05-12-2002
			AT 251481 T	15-10-2003
			AT 215389 T	15-04-2002
			AU 741693 B2	06-12-2001
			AU 8213798 A	30-12-1998
			AU 741218 B2	29-11-2001
			AU 8213898 A	30-12-1998
			AU 742913 B2	17-01-2002
			AU 8436498 A	30-12-1998
			BR 9809554 A	20-06-2000
			BR 9809980 A	01-08-2000
			BR 9809983 A	01-08-2000
			CA 2293484 A1	17-12-1998
			CA 2293487 A1	17-12-1998
			CA 2293488 A1	17-12-1998
			CN 1265601 T	06-09-2000
			DE 69804609 D1	08-05-2002
			DE 69804609 T2	12-09-2002
			DE 69818819 D1	13-11-2003
			DK 988077 T3	12-01-2004
			DK 986412 T3	22-07-2002
			EA 1396 B1	26-02-2001
			EG 21520 A	28-11-2001
			WO 9856444 A1	17-12-1998
			WO 9856445 A1	17-12-1998
			WO 9856446 A1	17-12-1998
			EP 1163922 A2	19-12-2001
			EP 0988077 A1	29-03-2000
			EP 0988078 A1	29-03-2000
			EP 0986412 A1	22-03-2000
			ES 2175737 T3	16-11-2002
			HK 1023956 A1	27-09-2002
			HR 980304 A1	30-04-1999
			HU 0003328 A2	28-02-2001
			ID 24128 A	06-07-2000
			JP 3487865 B2	19-01-2004
			JP 2000513632 T	17-10-2000
			JP 3487866 B2	19-01-2004
			JP 2000513633 T	17-10-2000
			JP 3487867 B2	19-01-2004
			JP 2000513634 T	17-10-2000
			NO 996085 A	09-02-2000
			NZ 501379 A	26-04-2002
			PL 337316 A1	14-08-2000
			PT 986412 T	30-09-2002
			TR 9903066 T2	21-07-2000
			TW 533865 Y	21-05-2003
			US 2002195102 A1	26-12-2002
			US 6474331 B1	05-11-2002
			US 6360739 B1	26-03-2002
WO 9626755	A	06-09-1996	AU 4729596 A	18-09-1996
			EP 0812219 A1	17-12-1997
			WO 9626755 A1	06-09-1996
			GB 2313787 A , B	10-12-1997
WO 0200281	A	03-01-2002	AU 7011301 A	08-01-2002
			AU 8464301 A	02-01-2002

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/12508

1317/EP 03/12508

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 0200281	A	CA 2407051 A1	27-12-2001	
		CA 2407262 A1	03-01-2002	
		EP 1330280 A2	30-07-2003	
		EP 1294421 A2	26-03-2003	
		GB 2365778 A	27-02-2002	
		GB 2366208 A	06-03-2002	
		GB 2366740 A	20-03-2002	
		GB 2365779 A	27-02-2002	
		JP 2003535656 T	02-12-2003	
		JP 2004501685 T	22-01-2004	
		WO 0197889 A2	27-12-2001	
		WO 0200281 A2	03-01-2002	
		US 2002078949 A1	27-06-2002	
		US 2002073996 A1	20-06-2002	
		US 2002078950 A1	27-06-2002	
		US 2002088463 A1	11-07-2002	
		AU 7011201 A	08-01-2002	
		CA 2407057 A1	03-01-2002	
		EP 1294420 A2	26-03-2003	
		GB 2372215 A	21-08-2002	
		WO 0200280 A2	03-01-2002	
		US 2002073997 A1	20-06-2002	
EP 1369139	A	10-12-2003	EP 1369139 A1	10-12-2003
			WO 03101514 A1	11-12-2003
WO 2004001664	A	31-12-2003	WO 2004001664 A1	31-12-2003